Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our present study showed evidence that CDKN1B Val 109 Gly variant is not related to PCa risk.
|
31257659 |
2019 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, proteasome inhibitors Bortezomib and MG132 transcriptionally down-regulate the expression of Skp2, and their combinations with FKB result in enhanced inhibitory effects on the growth of prostate cancer cell lines via synergistic down-regulation of Skp2 and up-regulation of p27/Kip1 and p21/WAF1 protein expression.
|
30885218 |
2019 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
miR-24 regulates CDKN1B/p27 expression in prostate cancer.
|
26847530 |
2016 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): potential implications on prostate cancer chemoprevention and therapy.
|
22856547 |
2013 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
eIF3b mRNA expression correlated to tumor grade, stage, and survival in human bladder and prostate cancer. eIF3b protein expression stratified survival in human bladder cancer. eIF3b depletion reduced in vitro cancer cell growth; inhibited G1-S cell-cycle transition by changing protein but not RNA expression of cyclin A, E, Rb, and p27Kip1; inhibited migration; and disrupted actin cytoskeleton and focal adhesions.
|
23575475 |
2013 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B.
|
23342268 |
2012 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Lack of expressions of Nkx3.1 and/or p27(KIP1) have been detected in most advanced PC and is associated with poor clinical progression.
|
19266349 |
2009 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer.
|
19176374 |
2009 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Overall, there was no significant association between CDKN1B V109G polymorphism and prostate cancer risk.
|
18645269 |
2008 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We aimed to find the frequency of these chromosomal abnormalities and assess their relationship to the prognosis of prostate cancer patients in relation to Gleason score and expression of p27Kip1.
|
17319789 |
2007 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that miR-221/222 can be regarded as a new family of oncogenes, directly targeting the tumor suppressor p27(Kip1), and that their overexpression might be one of the factors contributing to the oncogenesis and progression of prostate carcinoma through p27(Kip1) down-regulation.
|
17569667 |
2007 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We compared the involvement of PI3K/PTEN/Akt signaling in the regulation of the cell-cycle regulator p27(kip1) and investigated the mechanism of PI3K/PTEN/Akt modulation of p27(kip1) in the prostate cancer cell lines LNCaP, PC346, PC3, and DU145.
|
16425184 |
2006 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These include the ELAC2 (HPC2), MSR1, and RNASEL (HPC1) genes that have germline mutations in familial prostate cancer; AR, ATBF1, EPHB2 (ERK), KLF6, mitochondria DNA, p53, PTEN, and RAS that have somatic mutations in sporadic prostate cancer; AR, BRCA1, BRCA2, CHEK2 (RAD53), CYP17, CYP1B1, CYP3A4, GSTM1, GSTP1, GSTT1, PON1, SRD5A2, and VDR that have germline genetic variants associated with either hereditary and/or sporadic prostate cancer; and ANXA7 (ANX7), KLF5, NKX3-1 (NKX3.1), CDKN1B (p27), and MYC that have genomic copy number changes affecting gene function.
|
16267836 |
2006 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
An unusual gene dosage effect of p27kip1 in a mouse model of prostate cancer.
|
15701964 |
2005 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
TNF receptor 1 is involved in the induction of apoptosis by the cyclin dependent kinase inhibitor p27Kip1 in the prostate cancer cell line PC-3.
|
15545300 |
2005 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In light of the evidence for linkage between the chromosomal location of the CDKN1B gene (12p13) and prostate cancer susceptibility in several hereditary prostate cancer (HPC) populations, we hypothesized that sequence variants of CDKN1B play a role in HPC.
|
15026335 |
2004 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Our data are consistent with epistatic interactions between the PTEN and CDKN1B genes affecting risk for prostate cancer and demonstrate the utility of modeling epistatic effects in linkage analysis to detect susceptibility genes of complex diseases.
|
15185141 |
2004 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Herein, we examined single nucleotide polymorphic variants in the 3'-untranslated region of CDKN1A (p21(cip1)) and in codon 109 of CDKN1B (p27(kip1)) for association with advanced prostate cancer in a European-American population.
|
12727815 |
2003 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the effects of overexpression of p27(Kip1) in the human prostate carcinoma cell lines LNCaP, DU-145, and PC-3 in vitro and in vivo.
|
12210483 |
2002 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A candidate tumor suppressor gene at this locus is the cyclin dependent kinase inhibitor p27(kip1), which has been implicated as a marker of aggressive prostate carcinoma.
|
11536304 |
2001 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Together, these data implicate increased AKT activity in prostate tumor progression and androgen independence and suggest that diminished p27(Kip1) expression, which has been repeatedly associated with prostate cancer progression, may be a consequence of increased AKT activity.
|
10827191 |
2000 |
Prostate carcinoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
While immunohistochemical analysis has implicated p27/kip1 in prostate carcinoma, no previous studies had identified genetic abnormalities at this locus.
|
10840458 |
2000 |
Prostate carcinoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
However, the molecular-genetic analysis of a variety of human malignancies including prostate cancer failed to identify any alteration at the p27Kip1 gene locus, therefore suggesting a loss of p27Kip1 protein expression to result from post-transcriptional/post-translational events or from so far unknown regulatory mechanisms.
|
9864434 |
1999 |
Prostate carcinoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
These findings show a unique mechanism of cell growth inhibition by integrins and point to beta1C as an upstream regulator of p27(kip1) expression and, therefore, a potential target for tumor suppression in prostate cancer.
|
9927492 |
1999 |